ERBB2 and breast cancer: Similarly, a newly developed anti-HER2 ADC containing a potent anthracycline derivative payload (T-PNU) increased DAMP expression and enhanced efficacy when combined with an anti-PD-1 drug in a breast cancer model that developed resistance to other HER2-targeted therapies.